BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12019403)

  • 1. V804M RET mutation and familial medullary thyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriers.
    Lecube A; Hernandez C; Oriola J; Galard R; Gémar E; Mesa J; Simó R
    Surgery; 2002 May; 131(5):509-14. PubMed ID: 12019403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy.
    Siggelkow H; Melzer A; Nolte W; Karsten K; Hoppner W; Hufner M
    Eur J Endocrinol; 2001 May; 144(5):467-73. PubMed ID: 11331212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation.
    Feldman GL; Edmonds MW; Ainsworth PJ; Schuffenecker I; Lenoir GM; Saxe AW; Talpos GB; Roberson J; Petrucelli N; Jackson CE
    Surgery; 2000 Jul; 128(1):93-8. PubMed ID: 10876191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients.
    Niccoli-Sire P; Murat A; Rohmer V; Franc S; Chabrier G; Baldet L; Maes B; Savagner F; Giraud S; Bezieau S; Kottler ML; Morange S; Conte-Devolx B;
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3746-53. PubMed ID: 11502806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
    Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of V804M-mutated RET proto-oncogene associated with familial medullary thyroid cancer, report of the largest Turkish family.
    Basaran MN; Tuna MM; Karakılıç E; Doğan BA; İmga NN; Berker D; Güler S
    J Endocrinol Invest; 2015 May; 38(5):541-6. PubMed ID: 25501606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ret-proto-oncogene analysis in medullary thyroid carcinoma.
    O'Keeffe DA; Hill AD; Sheahan K; Ryan F; Barton D; Fitzgerald RJ; McDermott EW; O'Higgins NJ
    Ir J Med Sci; 1998; 167(4):226-30. PubMed ID: 9868860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations?
    Niccoli-Sire P; Murat A; Rohmer V; Gibelin H; Chabrier G; Conte-Devolx B; Visset J; Ronceray J; Jaeck D; Henry JF; Proye C; Carnaille B; Kraimps JL;
    Surgery; 2003 Dec; 134(6):1029-36; discussion 1036-7. PubMed ID: 14668737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families.
    Marsh DJ; McDowall D; Hyland VJ; Andrew SD; Schnitzler M; Gaskin EL; Nevell DF; Diamond T; Delbridge L; Clifton-Bligh P; Robinson BG
    Clin Endocrinol (Oxf); 1996 Feb; 44(2):213-20. PubMed ID: 8849577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2.
    Learoyd DL; Marsh DJ; Richardson AL; Twigg SM; Delbridge L; Robinson BG
    Arch Surg; 1997 Sep; 132(9):1022-5. PubMed ID: 9301617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome?
    Hansen HS; Torring H; Godballe C; Jäger AC; Nielsen FC
    Cancer; 2000 Aug; 89(4):863-7. PubMed ID: 10951350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804.
    Lombardo F; Baudin E; Chiefari E; Arturi F; Bardet S; Caillou B; Conte C; Dallapiccola B; Giuffrida D; Bidart JM; Schlumberger M; Filetti S
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1674-80. PubMed ID: 11932300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
    Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
    Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Study of RET protooncogene in multiple endocrine neoplasm 2A and in familial medullary thyroid carcinoma. Clinical pathological findings in asymptomatic carriers].
    Belli S; Storani ME; Dourisboure RJ; Podestá EJ; Solano AR
    Medicina (B Aires); 2003; 63(1):41-5. PubMed ID: 12673960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Consequences of clinical genetic analysis of RET proto-oncogene].
    Włoch J; Wygoda Z; Wiench M; Gubała E; Kula D; Oczko M; Lange D; Jarzab B
    Wiad Lek; 2001; 54 Suppl 1():406-14. PubMed ID: 12182057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive thyroidectomy in patients with hereditary medullary thyroid carcinoma found heterozygote for mutant RET proto-oncogene.
    Konstantinou E; Sapsakos Mariolis T; Fotis T; Mitsos A; Restos S; Mamoura K; Soultati A; Elefsiniotis I; Kapellakis G
    Pediatr Endocrinol Rev; 2010 Dec; 8(2):108-13. PubMed ID: 21150841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan.
    Iihara M; Yamashita T; Okamoto T; Kanbe M; Yamazaki K; Egawa S; Yamaguchi K; Obara T
    Jpn J Clin Oncol; 1997 Jun; 27(3):128-34. PubMed ID: 9255265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations.
    Fitze G; Schierz M; Bredow J; Saeger HD; Roesner D; Schackert HK
    Ann Surg; 2002 Nov; 236(5):570-5. PubMed ID: 12409662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma.
    Magalhães PK; de Castro M; Elias LL; Soares EG; Maciel LM
    Thyroid; 2004 Oct; 14(10):848-52. PubMed ID: 15588382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.